In8bio Inc Stock Performance
| INAB Stock | USD 0.23 0.02 8.00% |
In8bio has a performance score of 1 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of 1.75, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, In8bio will likely underperform. In8bio Inc currently owns a risk of 6.55%. Please check out In8bio Inc mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to decide if In8bio Inc will be following its current price history.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in In8bio Inc are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, In8bio may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 21.5 M |
In8bio |
In8bio Relative Risk vs. Return Landscape
If you would invest 24.00 in In8bio Inc on December 19, 2024 and sell it today you would lose (1.00) from holding In8bio Inc or give up 4.17% of portfolio value over 90 days. In8bio Inc is currently generating 0.1318% in daily expected returns and assumes 6.5471% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than In8bio, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
In8bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for In8bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as In8bio Inc, and traders can use it to determine the average amount a In8bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0201
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | INAB | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.55 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average In8bio is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of In8bio by adding it to a well-diversified portfolio.
In8bio Fundamentals Growth
In8bio Stock prices reflect investors' perceptions of the future prospects and financial health of In8bio, and In8bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on In8bio Stock performance.
| Return On Equity | -2.42 | ||||
| Return On Asset | -0.93 | ||||
| Current Valuation | 12.29 M | ||||
| Shares Outstanding | 72.48 M | ||||
| Price To Book | 1.27 X | ||||
| EBITDA | (30.44 M) | ||||
| Cash And Equivalents | 25.74 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 5.03 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (24.15 M) | ||||
| Earnings Per Share | (0.57) X | ||||
| Total Asset | 20.94 M | ||||
| Retained Earnings | (121.66 M) | ||||
About In8bio Performance
By analyzing In8bio's fundamental ratios, stakeholders can gain valuable insights into In8bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if In8bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if In8bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. In8Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.Things to note about In8bio Inc performance evaluation
Checking the ongoing alerts about In8bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for In8bio Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| In8bio Inc had very high historical volatility over the last 90 days | |
| In8bio Inc has some characteristics of a very speculative penny stock | |
| In8bio Inc has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| In8bio Inc currently holds about 25.74 M in cash with (24.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company shares are held by company insiders |
- Analyzing In8bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether In8bio's stock is overvalued or undervalued compared to its peers.
- Examining In8bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating In8bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of In8bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of In8bio's stock. These opinions can provide insight into In8bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |